Back to top
more

Thermo Fisher Scientific (TMO)

(Real Time Quote from BATS)

$501.74 USD

501.74
1,604,675

-11.34 (-2.21%)

Updated Nov 18, 2024 02:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 250)

Industry: Medical - Instruments

Zacks News

Merit Medical (MMSI) Soars to 52-Week High, Time to Cash Out?

Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Merit Medical (MMSI) Rallies 4.8% Post Q3 Earnings Beat

Merit Medical (MMSI) reported growth in revenues at Cardiovascular segment in the third quarter.

DaVita (DVA) Earnings Beat Estimates in Q3, Revenues Miss

DaVita (DVA) saw strength in dialysis services in the United States in the third quarter.

The Zacks Analyst Blog Highlights: Thermo Fisher, SAP, BMY, NextEra and Morgan Stanley

The Zacks Analyst Blog Highlights: Thermo Fisher, SAP, BMY, NextEra and Morgan Stanley

Omnicell (OMCL) Q3 Earnings Top, Pre-COVID-19 View Reinstated

Omnicell's (OMCL) Service and other revenues improve in Q3 despite the pandemic-led business challenges.

Integra (IART) Q3 Earnings Surpass Estimates, Margins Up

Integra's (IART) third-quarter 2020 results reflect mixed segmental performance with strong recovery trends due to coronavirus-led business disruptions.

Globus Medical (GMED) Q3 Earnings Beat, U.S. Business Strong

Globus Medical's (GMED) spinal implant business performance varies by region in Q3.

Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates

Baxter's (BAX) third-quarter results reflect strong performance across six of its business units.

IDEXX (IDXX) Earnings Beat Estimates in Q3, Margins Rise

IDEXX (IDXX) registered strong contribution from its CAG business in the third quarter despite pandemic-induced challenges.

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q2

ABIOMED's (ABMD) international Impella revenues improved in Q2.

CONMED (CNMD) Earnings and Revenues Surpass Estimates in Q3

CONMED's (CNMD) General Surgery unit witnessed revenue growth in Q3

Cerner (CERN) Q3 Earnings Surpass Estimates, Revenues Miss

Cerner's (CERN) third-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in margins.

PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) third-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.

QIAGEN (QGEN) Q3 Earnings Beat Estimates, FY20 Guidance Up

QIAGEN (QGEN) registeres robust revenue growth across geographies and both operating segments in Q3 despite the coronavirus-led economic crisis.

Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?

Is (TMO) Outperforming Other Medical Stocks This Year?

Boston Scientific (BSX) Q3 Earnings Top, Margins Decline

Boston Scientific's (BSX) Q3 earnings and revenues decline year over year but improve sequentially.

Sheraz Mian headshot

Top Analyst Reports for Thermo Fisher, SAP & Bristol-Myers

Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific (TMO), SAP SE (SAP) and Bristol-Myers Squibb (BMY).

LabCorp (LH) Extends Pact With Swedish for Coronavirus Lab Service

Under the extended alliance, LabCorp (LH) expects to expand its COVID-19 test capacity in the Seattle area.

Stock Market News for Oct 22, 2020

Benchmarks closed slightly lower on Wednesday as investors continued to look for signs of progress on a new fiscal stimulus deal.

Mark Vickery headshot

Verizon (VZ), Abbott (ABT), Thermo Fisher (TMO) Report Q3; Tesla (TSLA) After the Bell

Thermo Fisher (TMO) posted a big beat this morning, while Verizon (VZ) and Abbott (ABT) topped expectations more mildly.

Earnings Data Deluge

Earnings Data Deluge

Thermo Fisher (TMO) Q3 Earnings Beat on Life Sciences Sales

Significant COVID-19 led business expansions, as well as Thermo Fisher's (TMO) base business growth contribute to a stunning Q3 performance.

Align's (ALGN) ClinCheck Suite Now Commercially Available

Align Technology's (ALGN) ClinCheck treatment-planning software's commercial availability is expected to boost doctor performances due to ready availability of treatment plans.

Thermo Fisher Scientific (TMO) Q3 Earnings and Revenues Beat Estimates

Thermo Fisher (TMO) delivered earnings and revenue surprises of 28.83% and 10.03%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights include: DKS, ATVI, TMO, FBHS and TSM

Zacks.com featured highlights include: DKS, ATVI, TMO, FBHS and TSM